[Molecular Therapy-Methods & Clinical Development] Researchers developed a T cell receptor-like antibody that binds Synovial Sarcoma X breakpoint 2 (SSX2) peptide 41-49 in the context of HLA-A*-0201.
[Bone Marrow Transplantation] Researchers studied 57 patients in two centers who received myeloablative conditioning for cord blood transplant in Hurler syndrome, and reported a significant improvement in event-free survival with reduced incidence of graft failure and without any evidence of immune-mediated cytopenia in those patients that had received rituximab.
[European Journal of Cancer] Murine breast cancer cells were grown in both immune-competent and -deficient BALB/c mice, and tumors were irradiated by three fractions of 24 Gy. A PD-1 blockade and a phosphoinositide 3-kinase (PI3K)γδ inhibitor were then administered every other day for two weeks.
[Trials] In the Phase I trial, 18 patients with COVID-19-related pneumonia and/or lymphopenia with no oxygen requirement or with an oxygen need of less than or equal to 2.5 liters per minute in nasal cannula were assigned to two arms, based on the biology of the donor and the patient.
[Kite] Kite, a Gilead Company announced the FDA has granted approval for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
[Mucosal Immunology] T cells located in non-lymphoid tissues have come to prominence in recent years. CD8+ tissue-resident memory cells are important for tissue immune surveillance, provide an important line of defence against invading pathogens and show promise in cancer therapies.